Abstract
The aim of this retrospective study is to assess the prognostic value of tumor-infiltrating lymphocytes in triple negative breast carcinomas that lack both estrogen, progesterone receptors and Her2 amplification.The group of triple negative carcinomas has worse survival rates than other molecular subgroups of breast cancer, but at the same time it is very heterogeneous, and therefore requires the search for additional prognostic factors to improve the prognosis of patients.Materials and methods. The study included 350 samples of biopsies and surgical material from patients with stage I–III triple negative breast cancer who had not previously received chemotherapy. The median follow-up was 3.8 years for overall survival and 3.2 years for relapse-free survival. The prognostic value of tumor-infiltrating lymphocytes was evaluated by Kaplan–Meyer survival curves with a log-rank test, and one- and multifactor regression analysis according to the proportional risks Cox model.Results. Kaplan–Meier survival curves showed statistically significant relationships between tumor-infiltrating lymphocytes and overall and recurrence-free survival with a general trend to improve data for tumors with high lymphocyte volume. Proportional risks Cox model showed that tumors with a high number of tumor-infiltrating lymphocytes have statistically significantly better overall and recurrence-free survival rates (compared with tumors with a low number of tumor-infiltrating lymphocytes). The Kappa coefficient for interobserver variability was 0.79. It indicates a high level of agreement between pathologists in the evaluation of histological material.Conclusions. The high number of tumor-infiltrating lymphocytes in triple negative breast cancers is statistically significantly associated with better overall and recurrence-free survival rates. Assessment of tumor-infiltrating lymphocytes is rapid and does not require additional training, which makes this prognostic marker convenient to use.
Highlights
Мета роботи – оцінювання прогностичного значення пухлиноінфільтруючих лімфоцитів при тричі негативних карциномах молочної залози, що не мають рецепторів до естрогена, прогестерону й ампліфікації Her2
The aim of this retrospective study is to assess the prognostic value of tumor-infiltrating lymphocytes in triple negative breast carcinomas that lack both estrogen, progesterone receptors and Her2 amplification
The group of triple negative carcinomas has worse survival rates than other molecular subgroups of breast cancer, but at the same time it is very heterogeneous, and requires the search for additional prognostic factors to improve the prognosis of patients
Summary
A – концепція та дизайн дослідження; B – збір даних; C – аналіз та інтерпретація даних; D – написання статті; E – редагування статті; F – остаточне затвердження статті. Мета роботи – оцінювання прогностичного значення пухлиноінфільтруючих лімфоцитів при тричі негативних карциномах молочної залози, що не мають рецепторів до естрогена, прогестерону й ампліфікації Her. Для оцінювання прогностичного значення пухлиноінфільтруючих лімфоцитів побудували криві виживаності Каплана–Мейєра з логранковим тестом, а також виконали однофакторний і багатофакторний регресійний аналіз за пропорційною моделлю ризиків Кокса. Велика кількість пухлиноінфільтруючих лімфоцитів при тричі негативних карциномах молочної залози статистично вірогідно пов’язана з кращими показниками їхньої загальної та безрецидивної виживаності. Ключові слова: тричі негативний рак молочної залози, пухлиноінфільтруючі лімфоцити, мікрооточення пухлини, прогноз. The aim of this retrospective study is to assess the prognostic value of tumor-infiltrating lymphocytes in triple negative breast carcinomas that lack both estrogen, progesterone receptors and Her amplification. The group of triple negative carcinomas has worse survival rates than other molecular subgroups of breast cancer, but at the same time it is very heterogeneous, and requires the search for additional prognostic factors to improve the prognosis of patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
